ABT-107 is a selective α7nAChR agonist that does not affect Parkinsonism or cognitive performance; oral ABT-107 administration decreased levodopa-induced dyskinesia by 40–60% in MPTP-induced PD squirrel monkeys on levodopa/carbidopa therapy [72]. The gene discussed is CHRNA7; the disease is Dyskinesia.